Cefoxitin Sodium

  • #LGM Pharma is a Cefoxitin Sodium CAS# 33564-30-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 33564-30-6
  • AHFC code: 08:12.07.12
  • Synonyms: 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, sodium salt, (6R-cis)-, Betacef, Cefoxil, Cefoxitin, Cefoxitin and dextrose in duplex container, Cefoxitin sodium, Cefoxitin sodium salt, Cefoxotin sodium, Cenomycin, EINECS 251-574-6, L 620388, Mefoxin, Mefoxin in dextrose 5% in plastic container, Mefoxin in plastic container, Mefoxin in sodium chloride 0.9% in plastic container, Mefoxitin, Merxin, MK 206, Monosodium cefoxitin, Sodium (6R,7S)-3-(hydroxymethyl)-7-methoxy-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate carbamate (ester), UNII-Q68050H03T
  • ATC Code: J01DC01
  • Chemical Formula: C16-H16-N3-Na-O7-S2 C16-H16-N3-O7-S2.Na C16-H17-N3-O7-S2.Na
  • Molecular Weight: 449.4384
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB01331
  • SMILES: CO[C,,]1([C,,H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)Cc3cccs3.[Na+]
  • InChl: 1S/C16H17N3O7S2.Na/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19;/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22);/q;+1/p-1/t14-,16+;/m1./s1
  • PubChem: 441199
  • IUPAC:

Additional Details

Indication:
For the treatment of serious infections caused by susceptible strains microorganisms.
Pharmacodynamics:
Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria.
Mode of Action:
The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.
Metabolism:
Minimal (approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period).
Toxicity:
The acute intravenous LD50 in the adult female mouse and rabbit was about 8.0 g/kg and greater than 1.0 g/kg, respectively. The acute intraperitoneal LD50 in the adult rat was greater than 10.0 g/kg.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials